Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project)

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 746-755

  Vrijens, Bernard ^a,b   Claeys, Marc J ^c   Legrand, Victor ^b   Vandendriessche, Eef ^d   Van De Werf, Frans ^e  

^a MWV Healthcare   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

adherence; antiplatelet therapy; clopidogrel; once daily; ticagrelor; twice daily

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EXPOSURE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; DRUG EFFECTS; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84899099723     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12275     Document Type: Article

References (37)

1. Michelson AD,. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program 2011; 2011: 62-69.
2. Boden H, van der Hoeven BL, Karalis I, Schalij MJ, Jukema JW,. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. J Intern Med 2012; 271: 521-536.
3. Menozzi A, Lina D, Conte G, Mantovani F, Ardissino D,. Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother 2012; 13: 27-42.
4. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G,. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264.
5. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV,. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.
6. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D,. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
7. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US,. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
8. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC,. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
9. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
10. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G,. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
11. Teng R, Butler K,. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-496.
12. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF,. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
13. Butler K, Teng R,. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010; 70: 65-77.
14. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC,. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22-e33.
15. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R,. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28: 669-680.
16. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin ME,. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012; 18: 139-146.
17. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
18. Osterberg LG, Urquhart J, Blaschke TF,. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther 2010; 88: 457-459.
19. Comte L, Vrijens B, Tousset E, Gerard P, Urquhart J,. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007; 34: 549-558.
20. Hughes D,. Less is more: medicines that require less frequent administration improve adherence, but are they better? Pharmacoeconomics 2006; 24: 211-213.
21. Farmer KC,. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-1090.
22. Blaschke TF, Osterberg L, Vrijens B, Urquhart J,. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275-301.
23. Rubio A, Cox C, Weintraub M,. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22: 238-246.
24. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J,. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005; 45: 461-467.
25. Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentre F,. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther 2012; 92: 575-583.
26. Vrijens B, De GS, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J,. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73: 691-705.
27. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M,. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-1117.
28. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP,. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
29. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L,. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
30. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C,. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101-108.
31. Jennings LK,. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Crit Pathw Cardiol 2009; 8: 20-28.
32. Sweeny JM, Gorog DA, Fuster V,. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6: 273-282.
33. Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose. P, Fontana P, Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012; 125: 3201-3210.
34. Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C,. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother 2013; 57: 2265-2271.
35. Kruse W, Weber E,. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561-565.
36. Cramer J, Vachon L, Desforges C, Sussman NM,. Dose frequency and dose interval compliance with multiple anti-epileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111-1117.
37. Husted SE, Storey RF, Bliden K, Tantry US, Hoimark L, Butler K, Wei C, Teng R, Gurbel PA,. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet 2012; 51: 397-409.